Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Alternatives to antibiotics-a pipeline portfolio review.

Czaplewski L, Bax R, Clokie M, Dawson M, Fairhead H, Fischetti VA, Foster S, Gilmore BF, Hancock RE, Harper D, Henderson IR, Hilpert K, Jones BV, Kadioglu A, Knowles D, Ólafsdóttir S, Payne D, Projan S, Shaunak S, Silverman J, Thomas CM, Trust TJ, Warn P, Rex JH.

Lancet Infect Dis. 2016 Feb;16(2):239-51. doi: 10.1016/S1473-3099(15)00466-1. Epub 2016 Jan 13. Review.

PMID:
26795692
2.

Tackling antibiotic resistance.

Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI.

Nat Rev Microbiol. 2011 Nov 2;9(12):894-6. doi: 10.1038/nrmicro2693. Review.

3.

Francis Tally and the discovery and development of tigecycline: a personal reminiscence.

Projan SJ.

Clin Infect Dis. 2010 Jan 1;50 Suppl 1:S24-5. doi: 10.1086/647941.

PMID:
20067389
4.

Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Petersen PJ, Jones CH, Venkatesan AM, Mansour TS, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2009 Feb;53(2):370-84. doi: 10.1128/AAC.01047-08. Epub 2008 Nov 10.

5.

New technologies for the engineering of novel protein therapeutics and the personalization of medicine.

Dorner AJ, Projan S.

Curr Opin Pharmacol. 2008 Oct;8(5):598-9. doi: 10.1016/j.coph.2008.08.008. Epub 2008 Sep 18. No abstract available.

PMID:
18773971
6.

Whither antibacterial drug discovery?

Projan SJ.

Drug Discov Today. 2008 Apr;13(7-8):279-80. doi: 10.1016/j.drudis.2008.03.010. No abstract available.

PMID:
18405838
7.

Late stage antibacterial drugs in the clinical pipeline.

Projan SJ, Bradford PA.

Curr Opin Microbiol. 2007 Oct;10(5):441-6. Epub 2007 Oct 22. Review.

PMID:
17950658
8.

Tigecycline: a case study.

Loh E, Ellis-Grosse E, Petersen PJ, Sum PE, Projan S.

Expert Opin Drug Discov. 2007 Mar;2(3):403-18. doi: 10.1517/17460441.2.3.403.

PMID:
23484649
9.

(Genome) size matters.

Projan SJ.

Antimicrob Agents Chemother. 2007 Apr;51(4):1133-4. Epub 2007 Feb 12. No abstract available.

10.

Transcriptional profiling of a Staphylococcus aureus clinical isolate and its isogenic agr and sarA mutants reveals global differences in comparison to the laboratory strain RN6390.

Cassat J, Dunman PM, Murphy E, Projan SJ, Beenken KE, Palm KJ, Yang SJ, Rice KC, Bayles KW, Smeltzer MS.

Microbiology. 2006 Oct;152(Pt 10):3075-90.

PMID:
17005987
11.

Characterization of the Staphylococcus aureus heat shock, cold shock, stringent, and SOS responses and their effects on log-phase mRNA turnover.

Anderson KL, Roberts C, Disz T, Vonstein V, Hwang K, Overbeek R, Olson PD, Projan SJ, Dunman PM.

J Bacteriol. 2006 Oct;188(19):6739-56.

12.

Staphylococcal vaccines and immunotherapy: to dream the impossible dream?

Projan SJ, Nesin M, Dunman PM.

Curr Opin Pharmacol. 2006 Oct;6(5):473-9. Epub 2006 Jul 25. Review.

PMID:
16870507
13.
14.

Characterizing the effect of the Staphylococcus aureus virulence factor regulator, SarA, on log-phase mRNA half-lives.

Roberts C, Anderson KL, Murphy E, Projan SJ, Mounts W, Hurlburt B, Smeltzer M, Overbeek R, Disz T, Dunman PM.

J Bacteriol. 2006 Apr;188(7):2593-603.

15.

Transcription Profiling of the mgrA Regulon in Staphylococcus aureus.

Luong TT, Dunman PM, Murphy E, Projan SJ, Lee CY.

J Bacteriol. 2006 Mar;188(5):1899-910.

16.
17.

Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States.

Tenover FC, McDougal LK, Goering RV, Killgore G, Projan SJ, Patel JB, Dunman PM.

J Clin Microbiol. 2006 Jan;44(1):108-18.

18.

Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates.

McAleese F, Murphy E, Babinchak T, Singh G, Said-Salim B, Kreiswirth B, Dunman P, O'Connell J, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2005 Nov;49(11):4521-9.

19.

Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge.

Wu J, Kobayashi M, Sousa EA, Liu W, Cai J, Goldman SJ, Dorner AJ, Projan SJ, Kavuru MS, Qiu Y, Thomassen MJ.

Mol Cell Proteomics. 2005 Sep;4(9):1251-64. Epub 2005 Jun 12.

20.

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.

McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2005 May;49(5):1865-71.

21.

MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus.

Truong-Bolduc QC, Dunman PM, Strahilevitz J, Projan SJ, Hooper DC.

J Bacteriol. 2005 Apr;187(7):2395-405.

22.

Role of sigmaB in the expression of Staphylococcus aureus cell wall adhesins ClfA and FnbA and contribution to infectivity in a rat model of experimental endocarditis.

Entenza JM, Moreillon P, Senn MM, Kormanec J, Dunman PM, Berger-Bächi B, Projan S, Bischoff M.

Infect Immun. 2005 Feb;73(2):990-8.

23.

Comparative genomics of Staphylococcus aureus musculoskeletal isolates.

Cassat JE, Dunman PM, McAleese F, Murphy E, Projan SJ, Smeltzer MS.

J Bacteriol. 2005 Jan;187(2):576-92.

24.

Effect of mild acid on gene expression in Staphylococcus aureus.

Weinrick B, Dunman PM, McAleese F, Murphy E, Projan SJ, Fang Y, Novick RP.

J Bacteriol. 2004 Dec;186(24):8407-23.

25.

In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.

Weiss WJ, Petersen PJ, Murphy TM, Tardio L, Yang Y, Bradford PA, Venkatesan AM, Abe T, Isoda T, Mihira A, Ushirogochi H, Takasake T, Projan S, O'Connell J, Mansour TS.

Antimicrob Agents Chemother. 2004 Dec;48(12):4589-96.

26.

Antibacterial drug discovery: is it all downhill from here?

Projan SJ, Shlaes DM.

Clin Microbiol Infect. 2004 Nov;10 Suppl 4:18-22. Review.

27.

Uses of Staphylococcus aureus GeneChips in genotyping and genetic composition analysis.

Dunman PM, Mounts W, McAleese F, Immermann F, Macapagal D, Marsilio E, McDougal L, Tenover FC, Bradford PA, Petersen PJ, Projan SJ, Murphy E.

J Clin Microbiol. 2004 Sep;42(9):4275-83.

28.

Small molecules for small minds? The case for biologic pharmaceuticals.

Projan SJ, Gill D, Lu Z, Herrmann SH.

Expert Opin Biol Ther. 2004 Aug;4(8):1345-50. Review.

PMID:
15268667
29.

Global gene expression in Staphylococcus aureus biofilms.

Beenken KE, Dunman PM, McAleese F, Macapagal D, Murphy E, Projan SJ, Blevins JS, Smeltzer MS.

J Bacteriol. 2004 Jul;186(14):4665-84.

30.

Hydrophobic acetal and ketal derivatives of mannopeptimycin-alpha and desmethylhexahydromannopeptimycin-alpha: semisynthetic glycopeptides with potent activity against Gram-positive bacteria.

Dushin RG, Wang TZ, Sum PE, He H, Sutherland AG, Ashcroft JS, Graziani EI, Koehn FE, Bradford PA, Petersen PJ, Wheless KL, How D, Torres N, Lenoy EB, Weiss WJ, Lang SA, Projan SJ, Shlaes DM, Mansour TS.

J Med Chem. 2004 Jul 1;47(14):3487-90.

PMID:
15214775
31.

Microarray-based analysis of the Staphylococcus aureus sigmaB regulon.

Bischoff M, Dunman P, Kormanec J, Macapagal D, Murphy E, Mounts W, Berger-Bächi B, Projan S.

J Bacteriol. 2004 Jul;186(13):4085-99.

32.

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

Bauer G, Berens C, Projan SJ, Hillen W.

J Antimicrob Chemother. 2004 Apr;53(4):592-9. Epub 2004 Feb 25.

PMID:
14985271
33.

Effect of srtA and srtB gene expression on the virulence of Staphylococcus aureus in animal models of infection.

Weiss WJ, Lenoy E, Murphy T, Tardio L, Burgio P, Projan SJ, Schneewind O, Alksne L.

J Antimicrob Chemother. 2004 Mar;53(3):480-6. Epub 2004 Feb 4.

PMID:
14762051
34.

Phage-inspired antibiotics?

Projan S.

Nat Biotechnol. 2004 Feb;22(2):167-8. No abstract available.

PMID:
14755287
35.

Why is big Pharma getting out of antibacterial drug discovery?

Projan SJ.

Curr Opin Microbiol. 2003 Oct;6(5):427-30. Review.

PMID:
14572532
36.

Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon.

Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ.

Microbiology. 2003 Oct;149(Pt 10):2719-2732. doi: 10.1099/mic.0.26426-0.

PMID:
14523105
38.

Recurrent episodes of shock-like syndrome caused by the same strain of vancomycin-resistant Enterococcus faecium in a pediatric patient.

Papp L, McNeeley DF, Projan SJ, Bradford PA, Frost A, Nesin M.

Microb Drug Resist. 2003 Fall;9(3):307-12.

PMID:
12959410
39.

Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus.

Ruzin A, Severin A, Moghazeh SL, Etienne J, Bradford PA, Projan SJ, Shlaes DM.

Biochim Biophys Acta. 2003 May 2;1621(2):117-21.

PMID:
12726988
40.

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA.

Antimicrob Agents Chemother. 2003 Mar;47(3):972-8.

41.

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis.

Visalli MA, Murphy E, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2003 Feb;47(2):665-9.

42.

Global regulation of Staphylococcus aureus genes by Rot.

Saïd-Salim B, Dunman PM, McAleese FM, Macapagal D, Murphy E, McNamara PJ, Arvidson S, Foster TJ, Projan SJ, Kreiswirth BN.

J Bacteriol. 2003 Jan;185(2):610-9.

43.

Infectious diseases: back to the future?

Hagan P, Projan S, Rosamond J.

Trends Microbiol. 2002;10(10 Suppl):S1-2. No abstract available.

PMID:
12377560
44.

Antimicrobials: new solutions badly needed.

Projan SJ, Youngman PJ.

Curr Opin Microbiol. 2002 Oct;5(5):463-5. No abstract available.

PMID:
12354551
45.

New (and not so new) antibacterial targets - from where and when will the novel drugs come?

Projan SJ.

Curr Opin Pharmacol. 2002 Oct;2(5):513-22. Review.

PMID:
12324252
46.

The Genomic Aspect of Virulence, Sepsis, and Resistance to Killing Mechanisms in Staphylococcus aureus.

Cheung AL, Projan SJ, Gresham H.

Curr Infect Dis Rep. 2002 Oct;4(5):400-410.

PMID:
12228026
48.

Genomics in anti-infective drug discovery--getting to endgame.

Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ.

Curr Pharm Des. 2002;8(13):1099-118. Review.

PMID:
12052222
49.

Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria.

DeCenzo M, Kuranda M, Cohen S, Babiak J, Jiang ZD, Su D, Hickey M, Sancheti P, Bradford PA, Youngman P, Projan S, Rothstein DM.

J Antibiot (Tokyo). 2002 Mar;55(3):288-95.

50.

Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction.

Ruzin A, Severin A, Ritacco F, Tabei K, Singh G, Bradford PA, Siegel MM, Projan SJ, Shlaes DM.

J Bacteriol. 2002 Apr;184(8):2141-7.

Supplemental Content

Loading ...
Support Center